

## **A Letter from Our CEO**

### **Redefining How CNS Cancer Is Solved**

We founded Plus Therapeutics in 2019 to develop innovative radiotherapies for patients with central nervous system cancers. Since then, the CNS cancer need has continued to grow. We estimate that one million Americans are living with or at risk of CNS cancers, but patient survival in CNS cancers has not changed much in the last 50 years.

As the company has evolved and our market knowledge expanded, our vision for how we can make a meaningful difference in the lives of these patients and families has likewise evolved and expanded. We see clearly now that an integrative and holistic approach to CNS cancer is our best chance to improve outcomes for these patients.

CNS cancer is not a simple problem. It is a connected system of challenges spanning anatomy, pathophysiology, tumor diversity and genomic instability. These are the upstream drivers of unique downstream problems of diagnosis, therapeutic selection, disease monitoring, and clinical decision-making.

Under our new name, Cerenome, we accept the challenge of CNS cancer. With an integrative and cohesive approach to diagnosis, therapeutics and data insights, we intend as a company to prove these cancers are solvable. The name Cerenome signifies synergy and unity of the brain 'cere' with knowledge 'nome'.

As Cerenome, we will continue to advance our lead drug REYOBIQ through late-stage development for multiple CNS cancers and bring to market a complete portfolio of CSF diagnostic solutions under the CNSide brand. But this is only the foundation for what is to come. Soon, we will use native artificial intelligence and novel data insights to drive our strategy, operations, pipeline development, new product launches and partnering.

This next chapter reflects an ambitious but disciplined vision grounded in science, clinical evidence, and execution. We are not approaching CNS cancer as a series of disconnected problems. It is being approached as a solvable system by the world's only CNS oncology platform company, Cerenome. We invite you to join us on this worthy venture!

**Think it solvable.**

Marc H. Hedrick, MD  
President & Chief Executive Officer  
Cerenome, Inc. (Nasdaq: CNSY) effective August 3, 2026

